You are here

Development of a New 13c Aminopyrine Breath Test Kit

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 DK49946-01,
Agency Tracking Number: 29397
Amount: $703,025.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 1997
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1709 Dryden Road, Suite 1513
Houston, TX 77030
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Peter Klein
 () -
Business Contact
Phone: () -
Research Institution

The aminopyrine breath test (ABT) is a noninvasive assay of hepatic mixed- function oxidase that cothe active hepatocyte volume. This measurement has potential diagnostic utility in assessing liver dabuse, drug-drug interactions, and in predicting the survival of liver transplants. The use of 13C-ahampered by a lack of fully developed kits and analysis facilities. Phase I of this application coveconstruction of a kit embodying new concepts in breath collection, storage, and analysis to make theavailable to, and usable by, physicians. Kit design and production of 1000 kits will be completed beevaluation trials of Phase II. Clinical experience with the breath test kit and the diagnostic utiliPhase II will be used in the FDA approval process. In Phase III, approval of the ABT kit will enableincorporate its use for the first time into routine patient evaluation and management. The test kitMeretek Diagnostics, Inc., developers of the 13C-urea breath test for active Helicobacter pylori inf

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government